BUZZ-Entrada rises as FDA removes clinical hold on muscle-wasting therapy

Shares of drug developer Entrada Therapeutics TRDA.O rise 7.4% to $14 premarket

TRDA says FDA has removed clinical hold on co's therapy, ENTR-601-44, which is being studied for a type of muscle-wasting disorder called Duschenne muscular dystrophy (DMD) in the U.S.

Co receives authorization to initiate early-stage trial

In December 2022, the FDA placed a clinical hold on co's application to start trials of the therapy

Co plans to begin study enrollment in H1 2026

In the last 12 months, TRDA has fallen ~2%